Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
D000230:Adenocarcinoma / Q000188:drug therapy; D007516:Adenoma, Islet Cell / Q000188:drug therapy; D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000328:Adult; D000477:Alkylating Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D005909:Glioblastoma / Q000188:drug therapy; D006470:Hemorrhage / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009603:Nitroso Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014062:Tongue Neoplasms / Q000188:drug therapy; D014508:Urea / Q000627:therapeutic use*
D000477:Alkylating Agents; D009603:Nitroso Compounds; D014508:Urea; D002330:Carmustine